- Home
- HRMY vs SID Comparison
HRMY vs SID Comparison
Compare HRMY & SID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SID
- Stock Information
- Founded
- HRMY 2017
- SID 1941
- Country
- HRMY United States
- SID Brazil
- Employees
- HRMY N/A
- SID N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SID Steel/Iron Ore
- Sector
- HRMY Health Care
- SID Industrials
- Exchange
- HRMY Nasdaq
- SID Nasdaq
- Market Cap
- HRMY 1.6B
- SID 2.0B
- IPO Year
- HRMY 2020
- SID 1997
- Fundamental
- Price
- HRMY $34.09
- SID $1.73
- Analyst Decision
- HRMY Strong Buy
- SID Strong Sell
- Analyst Count
- HRMY 8
- SID 1
- Target Price
- HRMY $52.88
- SID $1.30
- AVG Volume (30 Days)
- HRMY 729.2K
- SID 2.0M
- Earning Date
- HRMY 05-06-2025
- SID 05-08-2025
- Dividend Yield
- HRMY N/A
- SID 12.87%
- EPS Growth
- HRMY 13.13
- SID N/A
- EPS
- HRMY 2.62
- SID N/A
- Revenue
- HRMY $744,852,000.00
- SID $7,063,567,739.00
- Revenue This Year
- HRMY $20.06
- SID $7.06
- Revenue Next Year
- HRMY $18.40
- SID $3.65
- P/E Ratio
- HRMY $12.76
- SID N/A
- Revenue Growth
- HRMY 20.62
- SID N/A
- 52 Week Low
- HRMY $26.47
- SID $1.27
- 52 Week High
- HRMY $41.61
- SID $2.85
- Technical
- Relative Strength Index (RSI)
- HRMY 69.87
- SID 60.45
- Support Level
- HRMY $29.82
- SID $1.63
- Resistance Level
- HRMY $30.61
- SID $1.72
- Average True Range (ATR)
- HRMY 1.15
- SID 0.06
- MACD
- HRMY 0.71
- SID 0.01
- Stochastic Oscillator
- HRMY 98.91
- SID 94.23
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.